Myopic macular neovascularization treatment: A 2-year follow-up of a real-life cohort
What is known The PRN injection regimen is widely used for treating myopic macular neovascularization (mMNV) due to its less aggressive nature and the potential risks of retinal break, retinal detachment, and other complications in highly myopic eyes. What is new At the 24-month follow-up, patients with mMNV treated with anti-VEGF agents in a PRN regimen showed no significant improvement in BCVA. Myopic MNV may be fallacy thought of as a less aggressive pathology and therefore is undertreated and perhaps may require a much more intensive injection schedule.
Authors
- Eran Greenbaum (ORCID: https://orcid.org/0000-0002-1027-3139)
- Reut Shor
- Roee Arnon
- Gilad Rabina (ORCID: https://orcid.org/0000-0002-9206-8373)
- Assaf Hilely
- Ori Segal (ORCID: https://orcid.org/0000-0001-5701-9544)
- Omer Trivizki (ORCID: https://orcid.org/0000-0003-3887-6238)
- Justin Lerann Shad
- Anat Loewenstein
Institutions
- University of California, Los Angeles (US)
- Tel Aviv Sourasky Medical Center (IL)
- Rabin Medical Center (IL)
- Meir Medical Center (IL)
Publication Details
- Journal
- Graefe s Archive for Clinical and Experimental Ophthalmology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1007/s00417-025-06973-9
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00